Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
You can also access detailed information by clicking Login in the website header.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
USA
Regulatory Approval:
Your Trustedworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Erwinaze (asparaginase Erwinia chrysanthemi) is an enzyme that depletes asparagine, an amino acid leukemia cells need to survive. It is indicated for:
Erwinaze is a prescription medicine and must be administered under the supervision of a qualified oncologist experienced in treating ALL.
This information is not a treatment plan. For personalized medical advice, consult your doctor and refer to the full prescribing information.
Step 1 – Search & request your medicine: The treating hospital submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant, cold-chain conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
Erwinaze (asparaginase Erwinia chrysanthemi) injection may be imported in the patient's name only, by patients or government hospitals, in line with India's import regulations for unapproved medicines. The following documentation is required:
The order is confirmed only after receipt and verification of a valid prescription from the doctor and, if applicable, an import permit.
Erwinaze (asparaginase Erwinia chrysanthemi injection) is a prescription medicine that legally requires a doctor's prescription to be dispensed. As of current publicly available information, Erwinaze is not commercially marketed in India.
However, patients in India can legally access Erwinaze through the Named Patient Program (NPP) — an import provision that allows patients to receive medicines approved in other countries but not yet marketed in India, under a doctor's prescription and proper regulatory documentation.
Erwinaze received US FDA approval for ALL patients hypersensitive to E. coli-derived asparaginase, ensuring full transparency throughout the process.
Erwinaze can be made available to patients, doctors, and hospitals across major cities in India, including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others.
The same active ingredient is also marketed as Erwinase in Europe and the UK; NPP can source either brand depending on availability.
Erwinaze is sourced directly from authorized channels in the country of origin and shipped to India under GDP-compliant, cold-chain logistics to preserve product integrity from dispatch to delivery.
Named Patient Program supports hospital access to Erwinaze for ALL patients hypersensitive to E. coli-derived asparaginase across major cities in India, coordinating documentation, sourcing, and delivery with treating oncologists.
Hospitals in Mumbai can access Erwinaze through NPP with support from treating pediatric and medical oncologists.
In Delhi, NPP coordinates with hospitals to facilitate timely access to Erwinaze for ALL treatment protocols.
Bangalore's oncology centers work with NPP to support patients requiring Erwinaze.
Hospitals in Chennai can access Erwinaze through NPP, with coordination between hospital pharmacy and the program's regulatory and logistics team.
Hyderabad's oncology centers support access coordination for Erwinaze through NPP.
NPP facilitates access to Erwinaze for hospitals in Kolkata for ALL chemotherapy protocols.
Hospitals in Pune can access Erwinaze through NPP with prescription-based coordination and cold-chain delivery support.
NPP supports access to Erwinaze for hospitals in Ahmedabad.
Hospitals in Kochi and across Kerala can access Erwinaze through NPP's regulated import pathway.
NPP coordinates access to Erwinaze for hospitals in Chandigarh and the surrounding region.
Hospitals in Jaipur can access Erwinaze through NPP for ALL treatment protocols.
NPP facilitates access to Erwinaze for hospitals in Lucknow and across Uttar Pradesh.
Hospitals in Bhubaneswar can access Erwinaze through NPP's coordinated import and delivery process.
NPP supports access to Erwinaze for hospitals in Guwahati and across the Northeast region.
NPP also supports hospitals in other Indian cities not listed above — contact the team to check availability and timelines for your location.
Written By: Nitin Goswami, Senior Medical Content Writer
Last Updated: 09 September 2026
Sources: FDA • CDSCO
Medically Reviewed By: Shilpi Banerjee, Registered Pharmacist (M.Pharm)
Last Updated: 09 September 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message